EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Transarterial chemoembolization with doxorubicin-loaded radiopaque beads for hepatocellular carcinoma: Safety, efficacy, and distribution

A Páez-Carpio, P Bermúdez, M Sanduzzi Zamparelli, M Barrufet, O Arrabal, A Forner, A Darnell, J Bruix, F Torres, M Reig, M Burrel

Radiología (English Edition) · 2025

DOI: 10.1016/j.rxeng.2025.101656 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Radiología (English Edition), 2025. Verfasst von A Páez-Carpio und 10 weiteren Autor:innen. Beteiligte Einrichtung: Grupo Barcelona Clinic Liver Cancer (BCLC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unidad de Oncología…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Doxorubicin, Chemoembolization, Therapeutic. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Fundación Científica Asociación Española Contra el Cáncer, Societat Catalana de Digestologia, Ministerio de Sanidad, Consumo y Bienestar Social.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: To evaluate the safety and efficacy of transarterial chemoembolization with radio-paque doxorubicin-loaded microspheres (rDEB-TACE) in patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This single-center, retrospective, observational study included all patients 18 years and older diagnosed with HCC and treated with rDEB-TACE from 2017 to 2020 at our institution. rDEB-TACE efficacy was evaluated by type of response after treatment at 1-,3- and 6-month, time to progression (TTP), and overall survival (OS). Safety of the techniquewas assessed based on the occurrence of adverse events (AEs). rDEB distribution was classified by overall distribution as type 1: intratumoral, type 2: intratumoral-feeding artery, and type 3: feeding artery and by intratumoral distribution in 0-50% and 50-100%. RESULTS: Twenty-one patients with 36 lesions treated with rDEB-TACE were included. Median follow-up time was 17 months (IQR: 6.0-45.5). Local and overall objective response at 1, 3 and 6 months was 86%, 85%, 84% and 91%, 78% and 84%, respectively. Median TTP was 27.0 months (95%CI: 8.9-28.1) and median OS was 54.9 months (95%CI: 16.3-NE). No major AEs were reported. The most common particle distribution was type 2 (69.4%). Concordance of particle distribution between intraprocedural cone beam CT and follow-up CT was high (kappa = 0.80). Most lesions treated showed a 50-100% intratumoral particle distribution, with higher rates of local (95.5% vs 71.4%) and overall objective response in this group (100% vs 71.4%) compared with the 0-50% group. CONCLUSION: rDEB-TACE is a safe and effective treatment for patients with HCC. Distribution of rDEB can be accurately assessed during and after the procedure and may predict early response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsDoxorubicinChemoembolization, TherapeuticAntibiotics, AntineoplasticHumansMaleRetrospective StudiesFemaleMicrospheresMiddle AgedAgedTreatment OutcomeContrast Media

Stichwörter der Autor:innen

Carcinoma hepatocellularCarcinoma hepatocelularChemoembolizationCone-beam CTDoxorrubicinaDoxorubicinMicroesferasMicrospheresQuimioembolizaciónTC de haz cónicoTerapéuticaTherapeutic

Substanzen

DoxorubicinAntibiotics, AntineoplasticContrast Media

Autor:innen und Institutionen

  • Grupo Barcelona Clinic Liver Cancer (BCLC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unidad de Oncología Hepática, Departamento de Angiorradiología, Hospital Clínic de Barcel…
  • Grupo Barcelona Clinic Liver Cancer (BCLC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unidad de Oncología Hepática, Unidad Hepática, Hospital Clínic de Barcelona, Barcelona, S…
  • Unidad de Bioestadística, Facultad de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Grupo Barcelona Clinic Liver Cancer (BCLC), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Unidad de Oncología Hepática, Departamento de Radiología Abdominal, Hospital Clínic de Ba…

Förderung

  • Fundación Científica Asociación Española Contra el Cáncer
  • Societat Catalana de Digestologia
  • Ministerio de Sanidad, Consumo y Bienestar Social
  • Instituto de Salud Carlos III

Zitieren

APA

Páez-Carpio, A., Bermúdez, P., Sanduzzi Zamparelli, M., Barrufet, M., Arrabal, O., Forner, A., Darnell, A., Bruix, J., Torres, F., Reig, M., & Burrel, M. (2025). Transarterial chemoembolization with doxorubicin-loaded radiopaque beads for hepatocellular carcinoma: Safety, efficacy, and distribution. Radiología (English Edition). https://doi.org/10.1016/j.rxeng.2025.101656

Vancouver

Páez-Carpio A, Bermúdez P, Sanduzzi Zamparelli M, Barrufet M, Arrabal O, Forner A, et al. Transarterial chemoembolization with doxorubicin-loaded radiopaque beads for hepatocellular carcinoma: Safety, efficacy, and distribution. Radiología (English Edition). 2025. doi:10.1016/j.rxeng.2025.101656

BibTeX
@article{PezCarpio2025,
  author = {Páez-Carpio, A and Bermúdez, P and Sanduzzi Zamparelli, M and Barrufet, M and Arrabal, O and Forner, A and Darnell, A and Bruix, J and Torres, F and Reig, M and Burrel, M},
  title = {Transarterial chemoembolization with doxorubicin-loaded radiopaque beads for hepatocellular carcinoma: Safety, efficacy, and distribution},
  journal = {Radiología (English Edition)},
  year = {2025},
  doi = {10.1016/j.rxeng.2025.101656}
}
Kostenlos starten →